Neuromuscular Electrical Stimulation
Neuromuscular electrical stimulation should be used with standard treatment to improve function, but no significant difference is seen in pain.
Pharmacologic, Physical, and Cognitive Pain Alleviation for Musculoskeletal Extremity/Pelvis Surgery (2021)
This guideline was produced in collaboration with METRC, with funding provided by the US Department of Defense. Endorsed by: SOMOS, OTA

Rationale

Two high quality (Stevens-Lapsley 2012, Feil 2011) and one moderate quality (Skowron 2019) study were reviewed. The two high quality studies showed improved function for Neuromuscular electrical stimulation (NMES) over standard of care, and one high quality study also showed improved function over Transcutaneous electrical nerve stimulation (TENS). The single moderate quality study showed decreased ROM and no change on QOL outcomes for NMES compared to standard treatment. Two studies (one high and one moderate quality) showed no changes in pain.

Benefits/Harms of Implementation

No studies reported adverse events and this technology is in widespread use. Risks appear to be low.

Cost Effectiveness/Resource Utilization

NEMS units are economical and may have low resource utilization in the hospital setting.

Feasibility

Intervention has been used extensively and is clearly feasible.

Future Research

Inconsistent results highlight the need for larger studies with an emphasis on heterogenous treatment effects. Further research into the effect of this intervention on opioid use and pain are needed, as well as cost effectiveness studies.